AbbVie Inc vs Meta Platforms Inc — how do they compare? AbbVie Inc trades at $247.73 (market cap $441.94B), while Meta Platforms Inc trades at $598.35 (market cap $1.53T). The key difference: Meta Platforms Inc is far larger — about 3.5× AbbVie Inc's market cap, and AbbVie Inc pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| ABBV | META | |
|---|---|---|
Market Cap | $441.94B | $1.53T |
Sector | Health | Media |
52-Week High | $263.58 | $790.00 |
52-Week Low | $197.38 | $525.72 |
Enterprise Value | $506.19B | $1.55T |
Dividend Yield | 2.77% | 0.35% |
Volume | — | 24,093,972 |
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
Meta Platforms trades at $594.92, up 0.48% with strong fundamentals including 81.75% gross margins and 29.84% net income margin. Recent Q1 2026 earnings beat expectations ($10.44 vs $6.70), though Q2 2026 missed ($6.18 vs $7.19). Technical indicators show bearish signals with current price near pivot point resistance at $598. The company maintains robust cash flow generation of $115.8B from operations in 2025.
Analyst consensus remains strongly bullish with 79% buy ratings and $761.95 price target, representing 28% upside. Key catalysts include AI leadership with Muse Spark launch and strong revenue growth trajectory. Risks include regulatory lawsuits, high capital expenditures, and competitive pressures in social media and AI markets.
Trailing returns across standard periods
Latest headlines on both assets
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →